b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30795862</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>16</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>17</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1090-2104</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>511</Volume>\n                    <Issue>2</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>04</Month>\n                        <Day>02</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Biochemical and biophysical research communications</Title>\n                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Synergism of myocardial \xce\xb2-adrenoceptor blockade and I<sub>1</sub>-imidazoline receptor-driven signaling: Kinase-phosphatase switching.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>363-368</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(19)30242-6</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2019.02.054</ELocationID>\n            <Abstract>\n                <AbstractText>Recently identified imidazoline receptors of the first type (I<sub>1</sub>Rs) on the cardiomyocyte\'s sarcolemma open a new field in calcium signaling research. In particular, it is interesting to investigate their functional interaction with other well-known systems, such as \xce\xb2-adrenergic receptors. Here we investigated the effects of I<sub>1</sub>Rs activation on L-type voltage-gated Ca<sup>2+</sup>-currents under catecholaminergic stress induced by the application of \xce\xb2-agonist, isoproterenol. Pharmacological agonist of I<sub>1</sub>Rs (I<sub>1</sub>-agonist), rilmenidine, and the putative endogenous I<sub>1</sub>-ligand, agmatine, have been shown to effectively reduce Ca<sup>2+</sup>-currents potentiated by isoproterenol. Inhibitory analysis shows that the ability to suppress voltage-gated Ca<sup>2+</sup>-currents by rilmenidine and agmatine is fully preserved in the presence of the protein kinase A blocker (PKA), which indicates a PKA-independent mechanism of their action. The blockade of NO synthase isoforms with 7NI does not affect the intrinsic effects of agmatine and rilmenidine, which suggests NO-independent signaling pathways triggered by I<sub>1</sub>Rs. A nonspecific serine/threonine protein phosphatase (STPP) inhibitor, calyculin A, abrogates effects of rilmenidine or agmatine on the isoproterenol-induced Ca<sup>2+</sup>-currents. Direct measurements of phosphatase activity in the myocardial tissues showed that activation of the I<sub>1</sub>Rs leads to stimulation of STPP, which could be responsible for the I<sub>1</sub>-agonist influences. Obtained data clarify peripheral effects that occur during activation of the I<sub>1</sub>Rs under endogenous catecholaminergic stress, and can be used in clinical practice for more precise control of heart contractility in some cardiovascular pathologies.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Maltsev</LastName>\n                    <ForeName>A V</ForeName>\n                    <Initials>AV</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Moscow Region, Pushchino, Institutskaya, 3, 142290, Russia; Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Butlerova 5\xd0\x90, 117485, Russia. Electronic address: alex.v.maltsev88@gmail.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Evdokimovskii</LastName>\n                    <ForeName>E V</ForeName>\n                    <Initials>EV</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Moscow Region, Pushchino, Institutskaya, 3, 142290, Russia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kokoz</LastName>\n                    <ForeName>Y M</ForeName>\n                    <Initials>YM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Moscow Region, Pushchino, Institutskaya, 3, 142290, Russia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>02</Month>\n                <Day>19</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>\n            <NlmUniqueID>0372516</NlmUniqueID>\n            <ISSNLinking>0006-291X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D058647">Adrenergic alpha-2 Receptor Agonists</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000318">Adrenergic beta-Agonists</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D054755">Imidazoline Receptors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011943">Receptors, Adrenergic, beta</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>70J407ZL5Q</RegistryNumber>\n                <NameOfSubstance UI="D000376">Agmatine</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.-</RegistryNumber>\n                <NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 3.1.3.2</RegistryNumber>\n                <NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>L628TT009W</RegistryNumber>\n                <NameOfSubstance UI="D007545">Isoproterenol</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>P67IM25ID8</RegistryNumber>\n                <NameOfSubstance UI="D000077769">Rilmenidine</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D058647" MajorTopicYN="N">Adrenergic alpha-2 Receptor Agonists</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000318" MajorTopicYN="N">Adrenergic beta-Agonists</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000376" MajorTopicYN="N">Agmatine</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D054755" MajorTopicYN="N">Imidazoline Receptors</DescriptorName>\n                <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007545" MajorTopicYN="N">Isoproterenol</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011943" MajorTopicYN="N">Receptors, Adrenergic, beta</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077769" MajorTopicYN="N">Rilmenidine</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Agmatine</Keyword>\n            <Keyword MajorTopicYN="Y">Cardiomyocyte</Keyword>\n            <Keyword MajorTopicYN="Y">Phosphatases</Keyword>\n            <Keyword MajorTopicYN="Y">Rilmenidine</Keyword>\n            <Keyword MajorTopicYN="Y">Voltage-gated calcium currents</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>24</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>02</Month>\n                <Day>10</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>18</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30795862</ArticleId>\n            <ArticleId IdType="pii">S0006-291X(19)30242-6</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.bbrc.2019.02.054</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'